Placebo-Controlled, Randomized, Prospective and Multicenter Trial of Everolimus in Castrated Resistant Prostate Cancer Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency
Overview
- Phase
- Phase 3
- Intervention
- Everolimus
- Conditions
- Prostate Cancer
- Sponsor
- Tianjin Medical University Second Hospital
- Enrollment
- 120
- Locations
- 4
- Primary Endpoint
- PFS
- Last Updated
- 7 years ago
Overview
Brief Summary
Investigators seek a new therapeutic strategy for castrated resistant prostate cancer(CRPC) patients with PI3K-AKT-mTOR signaling pathway deficiency by next generation sequencing(NGS).
Detailed Description
The prognosis of castrated resistant prostate cancer(CRPC) is very poor.Now,there is not an ideal therapeutic strategy.Further clarifying its mechanism and finding more effective therapeutic targets on this basis are the clinical problems to be solved urgently. More and more studies have confirmed that the role of PI3K-AKT-mTOR signaling pathway in the development of castration resistance to prostate cancer.By next generation sequencing of 115 patients with CRPC, investigators found that 22% of the patients had mutations in the PI3K-AKT-mTOR signaling related genes.Investigators found that 50% of the patients could benefit from the mTOR inhibitors.But the specific clinical significance and molecular mechanism are urgently needed to be elucidated. This project is based on the hypothesis that Everolimus can target CRPC patients with PI3K-AKT-mTOR signaling pathways deficiency.So,investigators intend to peform a prospective, randomized, controlled,multicenter clinical study to find potential therapeutic targets and treatment strategies for CRPC patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients diagnosed with advanced refractory castration resistant prostate cancer(CRPC).
- •Patients with histologically or cytologically confirmed prostate cancer.
- •Conventional treatment failed advanced CRPC patients,routine treatment including:radical prostatic cancer surgery,castration, ADT, amieton /inololamine new endocrine therapy,docetaxel intravenous drug resistance, or intolerance of toxic and side effects.
- •Patients must be able to provide blood samples or tissue samples for testing. The amount of blood samples should be able to meet the requirements of DNA extraction and quality control:
- •I.Sample type: DNA samples without RNA degradation and pollution free.
- •II.A single sample size of more than 500 ng (using Roche library platform,Illumina sequencing platform).
- •III.The sample concentration is more than 40 ng/L (using Roche building database platform; Illumina sequencing platform); IV.The purity of the sample is OD 260/280=1.8\~2;
- •After next generations of sequencing, all the patients were found to have defects in the PI3K-AKT-mTOR signaling pathway, including the following molecular markers: PI3K, AKT, mTOR, PTEN, TSC1, TSC2 and so on.
- •The expected survival time is more than 4 weeks.
- •Patients with Karnofsky(KPS) functional status score \> 60 and Eastern Cooperative Oncology Group(ECOG)state score 0-2 points.
Exclusion Criteria
- •Patients with other malignant tumors over the last 5 years.
- •Patients who received chemotherapy, biotherapy or other anticancer drugs is less than 4 weeks.
- •Patients with the following and above conditions:
- •I.Patients with symptomatic central nervous system metastases or spinal cord compression.
- •II.Patients with peripheral neuropathy symptoms, grade NCI(National Cancer Institute)\>gradeII.
- •III.Patients with any unstable systemic disease (including active infection, poor control of hypertension,unstable angina,congestive heart failure, liver, kidney or metabolic diseases).
- •IV.Patients with severe pulmonary interstitial changes, pulmonary fibrosis, and irreversible respiratory insufficiency.
- •V.Patients who are not receiving oral administration, need high energy intravenous nutrition, have undergone previous operations affecting absorption, active gastrointestinal ulcer and chronic diarrhea.
- •VI. Patients with serious, uncontrolled medical and infectious diseases. VII. Patients with severe electrolyte imbalance. VIII. Patients with diffuse intravascular coagulation. IX. Patients who known allergies to platinum and Everolimus targeted drugs
- •Patients with cognitive and psychological abnormality
Arms & Interventions
Everolimus & Best Supportive Care
Everolimus will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
Intervention: Everolimus
Placebo & Best Supportive Care
Placebo will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
Intervention: Placebo
Outcomes
Primary Outcomes
PFS
Time Frame: 36 months
Progression free survival of All the Evaluable Participants.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0).(Note: the appearance of one or more new lesions is also considered progression).
OS
Time Frame: 36months
Overall Survival of the Participants
Secondary Outcomes
- DCR(36 months)
- ORR(36 months)